Abstract
Chemokines and their corresponding receptors serve as pro-inflammatory and migratory signals for immune cells. CXCR3 and its corresponding ligands, CXCL9, CXCL10 and CXCL11, participate in the induction of immune responses against several foreign antigens. Numerous cells, including macrophages, NK cells and T lymphocytes, express CXCR3 and thus, expression of the receptor and its ligands can induce activity of these important immune cells against foreign antigens, including allogeneic grafts. Several parameters of the immune system participate in the induction and stimulation of powerful immune responses against allogeneic grafts. A thorough understanding of the parameters that regulate these responses can provide insights into new methods for immunotherapy during organ transplantation. The aim of this review is to address the most recent information regarding the roles played by CXCR3 and its corresponding ligands in the outcome of renal transplantation.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- NK cells:
-
natural killer cells
- DCs:
-
dendritic cells
- MIG:
-
monokine induced by gamma interferon
- I-TAC:
-
interferon-inducible T-cell alpha chemoattractant
- MHC:
-
major histocompatibility complex
- CXCL:
-
chemokine (C-X-C motif) ligand
- MDA5:
-
melanoma differentiation-associated gene 5
- GPCRs:
-
G-protein coupled receptors
- NF-κB:
-
nuclear factor kappa-light-chain-enhancer
- MAPK family:
-
mitogen-activated protein kinase family
- Pyk2:
-
protein tyrosine kinase 2
- ELR:
-
glutamic acid-leucine-arginine motif
References
Zhang Z-X, Huang X, Jiang J, et al. Natural killer cells mediate long-term kidney allograft injury. Transplantation 2015; 99: 916–24.
Betjes M. Clinical consequences of circulating CD28 negative T cells for solid organ transplantation. Transpl Int 2016; 29: 274–84.
Zare-Bidaki M, Karimi-Googheri M, Hassanshahi G, Zainodini N, Arababadi MK. The frequency of CCR5 promoter polymorphisms and CCR5 Δ 32 mutation in Iranian populations. Iran J Basic Med Sci 2015; 18: 312.
Steinmetz OM, Turner J-E, Paust H-J, et al. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis. J Immunol 2009; 183: 4693–704.
Schena FP. Management of patients with chronic kidney disease. Intern Emerg Med 2011; 6: 77–83.
Reese PP, Boudville N, Garg AX. Living kidney donation: outcomes, ethics, and uncertainty. Lancet 2015; 385: 2003–13.
Geramizadeh B, Azarpira N, Ayatollahi M, et al. Value of serum cystatin C as a marker of renal function in the early post kidney transplant period. Saudi J Kidney Dis Transpl 2009; 20: 1015.
Yaghobi R, Ramzi M, Dehghani S. The role of different risk factors in clinical presentation of hemorrhagic cystitis in hematopoietic stem cell transplant recipients. Transplant Proc 2009; 41: 2900–2.
Salvadori M, Rosso G, Bertoni E. Update on ischemia-reperfusion injury in kidney transplantation: pathogenesis and treatment. World J Transplant 2015; 5: 52.
Hejr S, Karimi MH, Yaghobi R, Kamali-Sarvestani E, Geramizadeh B, Roozbeh J. Association of IL-17, IL-21, and IL-23R gene polymorphisms with HBV infection in kidney transplant patients. Viral Immunol 2013; 26: 201–6.
Lacotte S, Brun S, Muller S, Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 2009; 1173: 310–7.
Loetscher M, Loetscher P, Brass N, Meese E, Moser B. Lymphocytespecific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 1998; 28: 3696–705.
Hickman HD, Reynoso GV, Ngudiankama BF, et al. CXCR3 chemokine receptor enables local CD8+ T cell migration for the destruction of virus-infected cells. Immunity 2015; 42: 524–37.
Hodge DL, Schill WB, Wang JM, et al. IL-2 and IL-12 alter NK cell responsiveness to IFN-γ-inducible protein 10 by down-regulating CXCR3 expression. J Immunol 2002; 168: 6090–8.
Fenwick PS, Macedo P, Kilty IC, Barnes PJ, Donnelly LE. Effect of JAK inhibitors on release of CXCL9, CXCL10 and CXCL11 from human airway epithelial cells. PLoS One 2015; 10: e0128757.
Van Raemdonck K, Van den Steen PE, Liekens S, Van Damme J, Struyf S. CXCR3 ligands in disease and therapy. Cytokine Growth Factor Rev 2015; 26: 311–27.
Venner JM, Hidalgo LG, Famulski KS, Chang J, Halloran PF. The Molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. Am J Transpl 2015; 15: 1336–48.
Romagnani P, Maggi L, Mazzinghi B, et al. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J Allergy Clin Immunol 2005; 116: 1372–9.
Shahabuddin S, Ji R, Wang P, et al. CXCR3 chemokine receptorinduced chemotaxis in human airway epithelial cells: role of p38 MAPK and PI3K signaling pathways. Am J Physiol Cell Physiol 2006; 291: C34–9.
Meiser A, Mueller A, Wise EL, et al. The chemokine receptor CXCR3 is degraded following internalization and is replenished at the cell surface by de novo synthesis of receptor. J Immunol 2008; 180: 6713–24.
Dagan-Berger M, Feniger-Barish R, Avniel S, et al. Role of CXCR3 carboxyl terminus and third intracellular loop in receptor-mediated migration, adhesion and internalization in response to CXCL11. Blood 2006; 107: 3821–31.
Huang H, Xu X, Yao C, et al. Serum levels of CXCR3 ligands predict T cell-mediated acute rejection after kidney transplantation. Mol Med Rep 2014; 9: 45–50.
Reid-Yu SA, Tuinema BR, Small CN, Xing L, Coombes BK. CXCL9 contributes to antimicrobial protection of the gut during Citrobacter rodentium infection independent of chemokine-receptor signaling. PLoS Pathog 2015; 11, e1004648–e.
Trotta T, Costantini S, Colonna G. Modelling of the membrane receptor CXCR3 and its complexes with CXCL9, CXCL10 and CXCL11 chemokines: putative target for new drug design. Mol Immunol 2009; 47: 332–9.
Vazirinejad R, Ahmadi Z, Kazemi Arababadi M, Hassanshahi G, Kennedy D. The biological functions, structure and sources of CXCL10 and its outstanding part in the pathophysiology of multiple sclerosis. Neuroimmunomodulation 2014; 21: 322–30.
Booth V, Keizer DW, Kamphuis MB, Clark-Lewis I, Sykes BD. The CXCR3 binding chemokine IP-10/CXCL10: structure and receptor interactions. Biochemistry 2002; 41: 10418–25.
Severin IC, Gaudry J-P, Johnson Z, et al. Characterization of the chemokine CXCL11-heparin interaction suggests two different affinities for glycosaminoglycans. J Biol Chem 2010; 285: 17713–24.
Booth V, Clark-Lewis I, Sykes BD. NMR structure of CXCR3 binding chemokine CXCL11 (ITAC). Protein Sci 2004; 13: 2022–8.
Bieche I, Chavey C, Andrieu C, et al. CXCchemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer 2007; 14: 1039–52.
Lasagni L, Grepin R, Mazzinghi B, et al. PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion. Blood 2007; 109: 4127–34.
Heidt S, Shankar S, Muthusamy AS, San Segundo D, Wood KJ. Pretransplant serum CXCL9 and CXCL10 levels fail to predict acute rejection in kidney transplant recipients receiving induction therapy. Transplantation 2011; 91: e59–61.
Lin Q, Song Y, Zhu X, Yang S, Zheng J. Expressions of CXCL9, CXCL10 and CXCL11 in renal tubular epithelial cells induced by IFN-γ. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2013; 29: 137–40.
Panzer U, Reinking RR, Steinmetz OM, et al. CXCR3 and CCR5 positive T-cell recruitment in acute human renal allograft rejection. Transplantation 2004; 78: 1341–50.
Segerer S, Böhmig GA, Exner M, Kerjaschki D, Regele H, Schlöndorff D. Role of CXCR3 in cellular but not humoral renal allograft rejection. Transpl Int 2005; 18: 676–80.
Inston N, Drayson M, Ready A, Cockwell P. Serial changes in the expression of CXCR3 and CCR5 on peripheral blood lymphocytes following human renal transplantation. Exp Clin Transplant 2007; 5: 638–42.
Reiners J, Henne T, Offner G, et al. Mig, IP-10, and CXCR3 gene expression is predictive for the individual response of children with chronic allograft nephropathy to mycophenolate mofetil. Transplant Proc 2002: 2217–8.
Akalin E, Dikman S, Murphy B, Bromberg J, Hancock W. Glomerular infiltration by CXCR3+ ICOS+ activated T cells in chronic allograft nephropathy with transplant glomerulopathy. Am J Transpl 2003; 3: 1116–20.
Hoffmann U, Segerer S, Rümmele P, et al. Expression of the chemokine receptorCXCR3in human renal allografts–a prospective study. Nephrol Dial Transplant 2006; 21: 1373–81.
Hu H, Aizenstein BD, Puchalski A, Burmania JA, Hamawy MM, Knechtle SJ. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transpl 2004; 4: 432–7.
Tatapudi RR, Muthukumar T, Dadhania D, et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 2004; 65: 2390–7.
Jackson JA, Kim EJ, Begley B, et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transpl 2011; 11: 2228–34.
Rotondi M, Rosati A, Buonamano A, et al. High pretransplant serum levels of CXCL10/IP-10 are related to increased risk of renal allograft failure. Am J Transpl 2004; 4: 1466–74.
Brouard S, Soulillou JP. Pre-transplant serum level of CXCL9 as a biomarker of acute rejection and graft failure risk in kidney transplantation. Transpl Int 2010; 23: 461–2.
Rotondi M, Netti GS, Lazzeri E, et al. High pretransplant serum levels of CXCL9 are associated with increased risk of acute rejection and graft failure in kidney graft recipients. Transpl Int 2010; 23: 465–75.
Lazzeri E, Rotondi M, Mazzinghi B, et al. High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy. Transplantation 2005; 79: 1215–20.
Schaub S, Nickerson P, Rush D, et al. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transpl 2009; 9: 1347–53.
Hricik D, Nickerson P, Formica R, et al. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transpl 2013; 13: 2634–44.
Kakuta Y, Okumi M, Miyagawa S, et al. Blocking of CCR5 and CXCR3 suppresses the infiltration of macrophages in acute renal allograft rejection. Transplantation 2012; 93: 24–31.
Furuichi K, Wada T, Kitajikma S, et al. IFN-inducible protein 10 (CXCL10) regulates tubular cell proliferation in renal ischemiareperfusion injury. Nephron Exp Nephrol 2008; 76: 320–8.
Imaizumi T, Aizawa-Yashiro T, Tsuruga K, et al. Melanoma differentiation-associated gene 5 regulates the expression of a chemokine CXCL10 in human mesangial cells: implications for chronic inflammatory renal diseases. Tohoku J Exp Med 2012; 228: 17–26.
Higurashi M, Ohya Y, Joh K, et al. Increased urinary levels of CXCL5, CXCL8 and CXCL9 in patients with Type 2 diabetic nephropathy. J Diabetes Complications 2009; 23: 178–84.
Petrovic-Djergovic D, Popovic M, Chittiprol S, Cortado H, Ransom R, Partida-Sánchez S. CXCL10induces the recruitment of monocytederived macrophages into kidney, which aggravate puromycin aminonucleoside nephrosis. Clin Exp Immunol 2015; 180: 305–15.
Nguyen M-TJ, Fryml E, Sahakian SK, et al. Pretransplantation recipient regulatory T cell suppressive function predicts delayed and slow graft function after kidney transplantation. Transplantation 2014; 98: 745–53.
Hoerning A, Kohler S, Jun C, et al. Peripherally circulating CD4(+) FOXP3(+) CXCR3(+)Tregulatory cells correlate with renal allograft function. Scand J Immunol 2012; 76: 320–8.
Jun C, Qingshu L, Ke W, et al. Protective effect of CXCR3 CD4 CD25 Foxp3 regulatory T cells in renal ischemia-reperfusion injury. Mediators Inflamm 2015; 501: 360973.
Nakaya I, Wada T, Furuichi K, et al. Blockade of IP-10/CXCR3 promotes progressive renal fibrosis. Nephron Exp Nephrol 2007; 107: e12–21.
Sakaguchi S. Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345–52.
Katzman SD, Hoyer KK, Dooms H, et al. Opposing functions of IL-2 and IL-7 in the regulation of immune responses. Cytokine 2011; 56: 116–21.
Menke J, Zeller GC, Kikawada E, et al. CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease. J Am Soc Nephrol 2008; 19: 1177–89.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Dabiri, S., Kariminik, A. & Kennedy, D. The role of CXCR3 and its ligands in renal transplant outcome. Eur Cytokine Netw 27, 34–40 (2016). https://doi.org/10.1684/ecn.2016.0375
Published:
Issue Date:
DOI: https://doi.org/10.1684/ecn.2016.0375